NCT05400330 · Phase 1 · ACTIVE NOT RECRUITING
Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease
This study follows people who already received LX1001, an experimental gene therapy that delivers a protective APOE2 gene into the brain. It mainly checks long-term safety. It also tracks brain scans, spinal fluid markers, and thinking tests. It is a Phase 1 trial, meaning an early safety look, not proof that it works.
You may qualify if
- Participants who received LX1001 in study LX1001-01
You're excluded if
- Participants with any clinically significant medical condition that, in the opinion of the investigator, would pose a risk to participant safety
- Participants who agree not to post their personal medical data in relation to this study or any study information online, including social media sites, until all participants have completed all LX1001 clinical studies, including long-term follow-up.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-07-01